Last reviewed · How we verify

LaNova Medicines Limited — Portfolio Competitive Intelligence Brief

LaNova Medicines Limited pipeline: 0 marketed, 0 filed, 2 Phase 3, 2 Phase 2. Recent regulatory actions, upcoming PDUFA, patent timeline, top competitor overlap.

0 marketed 0 filed 2 Phase 3 2 Phase 2 4 Phase 1 Live · 30-min refresh

Portfolio leaders (marketed + Phase 3 / filed)

DrugGenericPhaseClassTargetAreaFirst approval
LM-108 in combination with Toripalimab LM-108 in combination with Toripalimab phase 3 Immunotherapy combination (checkpoint inhibitor + unknown immunomodulator) PD-1 (Toripalimab); LM-108 target unknown Oncology
Paclitaxel injection intravenous infusion Paclitaxel injection intravenous infusion phase 3 Taxane; microtubule stabilizer β-tubulin Oncology

Therapeutic area mix

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this portfolio.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this portfolio.

Patent timeline (forward window)

No upcoming patent expiries for this portfolio.

Competitive overlap (companies sharing drug classes)

  1. Akeso · 1 shared drug class
  2. Aravive, Inc. · 1 shared drug class
  3. Athenex, Inc. · 1 shared drug class
  4. Barts & The London NHS Trust · 1 shared drug class
  5. BeyondSpring Pharmaceuticals Inc. · 1 shared drug class
  6. Bio-Thera Solutions · 1 shared drug class
  7. Dai, Guanghai · 1 shared drug class
  8. Fujian Medical University · 1 shared drug class

Subscribe to ongoing alerts

Every new pipeline event for LaNova Medicines Limited:

Cite this brief

Drug Landscape (2026). LaNova Medicines Limited — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/lanova-medicines-limited. Accessed 2026-05-16.

Related